

# Journal of Visualized Experiments

## Application of dorsal root ganglia primary cultures to studies of neurotransmitter release

--Manuscript Draft--

<b>Article Type:</b>	Invited Methods Article - JoVE Produced Video
<b>Manuscript Number:</b>	JoVE57569R1
<b>Full Title:</b>	Application of dorsal root ganglia primary cultures to studies of neurotransmitter release
<b>Keywords:</b>	dorsal root ganglia, DRG, primary culture, neuronal cultures, CGRP, substance P, neurotransmitter, sensory neuron, pain, pain transmission, nociception
<b>Corresponding Author:</b>	Ya-Tin Lin, Ph.D. Chang Gung University Taoyuan, -- TAIWAN
<b>Corresponding Author's Institution:</b>	Chang Gung University
<b>Corresponding Author E-Mail:</b>	qpilipalaq@gmail.com
<b>First Author:</b>	Ya-Tin Lin, Ph.D.
<b>Other Authors:</b>	Jin-Chung Chen
<b>Author Comments:</b>	Please change the corresponding author from Ya-Tin Lin to Jin-Chung Chen for us. Thank you very much!
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
If this article needs to be "in-press" by a certain date, please indicate the date below and explain in your cover letter.	

Dear Dr. DSouza,

Thank you very much for your letter of Dec 20 in regard of our submitted article (**Ms. No. JoVE57569**) entitled “Application of dorsal root ganglia primary cultures to studies of neurotransmitter release”. In this revised version, we have made several modifications based on you and reviewer’s valid suggestion. In addition, we prepare a response letter to answer the raised questions point-by-point. In particular, we have added the methods of siRNA transfection and CGRP/SP ELISA. Since the transfection and ELISA protocol are based on the guidelines provided by commercial kits, we did not describe in detail or made extra discussion on these methods. The modifications in the text are highlighted with yellow marks and the steps for video filming are highlighted in gray. We wish you and reviewers could satisfy with the current version and accept for publication soon. Thank you very much for your assistance.

Sincerely yours,

Jin-Chung Chen, Ph.D.

Director, Graduate Institute of Biomedical Sciences

Professor, Department of Physiology and Pharmacology

School of Medicine, Chang Gung University

Wenhua 1st Road, Guishan Dist, Taoyuan City

Taiwan, R.O.C. 33302

Tel: 011-886-3-2118800 ext 5282

Fax: 011-886-3-2118700

e-mail: [jinchen@mail.cgu.edu.tw](mailto:jinchen@mail.cgu.edu.tw)

**TITLE:**

Dorsal Root Ganglia Isolation and Primary Culture to Study Neurotransmitter Release

**AUTHORS & AFFILIATIONS:**

Ya-Tin Lin<sup>1</sup> and Jin-Chung Chen<sup>1,2,3</sup>

<sup>1</sup>Graduate Institute of Biomedical Sciences, Department of Physiology and Pharmacology, Chang Gung University, Taoyuan, Taiwan

<sup>2</sup>Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan

<sup>3</sup>Neuroscience Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan

**CORRESPONDING AUTHOR:**

Jin-Chung Chen

Email Address: jinchen@mail.cgu.edu.tw

Tel: (886)3-211-8800

**EMAIL ADDRESSES OF CO-AUTHORS:**

yatin@mail.cgu.edu.tw

**KEYWORDS:**

Dorsal root ganglia, DRG, primary culture, neuronal cultures, CGRP, substance P, neurotransmitter, sensory neuron, pain, pain transmission, nociception

**SHORT ABSTRACT:**

Dorsal root ganglia (DRG) primary cultures are frequently used to study physiological functions or pathology-related events in sensory neurons. Here, we demonstrate the use of lumbar DRG cultures to detect the release of neurotransmitters after neuropeptide FF receptor type 2 stimulation with a selective agonist.

**LONG ABSTRACT:**

Dorsal root ganglia (DRG) contain cell bodies of sensory neurons. This type of neuron is pseudo-unipolar, with two axons that innervate peripheral tissues, such as skin, muscle and visceral organs, as well as the spinal dorsal horn of the central nervous system. Sensory neurons transmit somatic sensation, including touch, pain, thermal, and proprioceptive sensations. Therefore, DRG primary cultures are widely used to study the cellular mechanisms of nociception, physiological functions of sensory neurons, and neural development. The cultured neurons can be applied in studies involving electrophysiology, signal transduction, neurotransmitter release, or calcium imaging. With DRG primary cultures, scientists may culture dissociated DRG neurons to monitor biochemical changes in single or multiple cells, overcoming many of the limitations associated with *in vivo* experiments. Compared to commercially available DRG-hybridoma cell lines or immortalized DRG neuronal cell lines, the composition and properties of the primary cells are much more similar to sensory neurons in tissue. However, due to the limited number of cultured DRG primary cells that can be isolated from a single animal, it is difficult to perform high-throughput screens for drug targeting studies. In the current article, procedures for DRG

collection and culture are described. In addition, we demonstrate the treatment of cultured DRG cells with an agonist of neuropeptide FF receptor type 2 (NPFFR2) to induce the release of peptide neurotransmitters (calcitonin gene-related peptide (CGRP) and substance P (SP)).

## **INTRODUCTION:**

The cell bodies of sensory neurons are contained within DRG. These neurons are pseudo-unipolar and innervate both peripheral tissues and the central nervous system. The peripheral nerve endings of sensory neurons are found in muscle, skin, visceral organs, and bone, among other tissues. They transmit peripheral sensation signals to nerve endings in the spinal dorsal horn and the signals are then transmitted to the brain via different ascending pathways of somatic sensation<sup>1,2</sup>. Somatic sensation enables the body to feel (*i.e.*, touch, pain, and thermal sensations) and perceive movement and spatial orientation (proprioceptive sensations)<sup>1,3</sup>. There are four subclasses of primary afferent axons, including group I (A $\alpha$ ) fibers that respond to proprioception of skeletal muscles, group II (A $\beta$ ) fibers that respond to mechanoreceptors of the skin, and group III (A $\delta$ ) and group V (C) fibers that respond to pain and temperature. Only the C fibers are unmyelinated, while the rest are myelinated to different degrees.

Nociceptors are primary sensory neurons, which are activated by noxious stimuli (mechanical, thermal, and chemical stimulation) that carry potential for tissue damage. These neurons are composed of myelinated A $\delta$  fibers and unmyelinated C fibers<sup>1,4</sup>. The A $\delta$  fibers express the receptors for nerve growth factor (NGF, trkA receptor), CGRP, and SP. The C fibers are classified as either peptidergic and non-peptidergic C fibers. On the other hand, the non-peptidergic C fibers express the receptors for glial-derived neurotrophic factor (GDNF, RET, and GFR receptors), isolectin IB4, and ATP-gated ion channel subtype (P2X3)<sup>5-7</sup>. Nociceptors can be distinguished by the expression of ion channels and activated by neurotrophic factors, cytokines, neuropeptides, ATP, or other chemical compounds<sup>8</sup>. Upon stimulation, neurotransmitters, including CGRP, SP, and glutamate may be released from sensory neuron terminals in the spinal dorsal horn to transmit nociceptive signals<sup>2</sup>. DRG are not only composed of neurons, but also contain satellite glial cells. Satellite cells surround the sensory neurons and provide mechanical and metabolic support<sup>9,10</sup>. Interestingly, there is a growing body of evidence indicating that satellite glial cells in the DRG may be involved in regulating pain sensation<sup>11</sup>.

Sensory neurons have been reported to be the most frequently used primary neuronal cells<sup>12</sup> and have been utilized for electrophysiology, signal transduction, and neurotransmitter release studies. They are also commonly used to explore the cellular mechanisms of neuronal development, inflammatory pain, neuropathic pain, skin sensation (like itch), and axon outgrowth<sup>12-15</sup>. DRG primary cultures can be cultured as dissociated neurons to assess biochemical changes in single or multiple cells, allowing scientists to perform studies that cannot be performed in experimental subjects. Recently, DRG were successfully cultured from human organ donors which might greatly benefit translational research<sup>16</sup>. On the other hand, sensory neurons can also be cultured as DRG explants. The DRG explants preserve the original tissue architecture of the neurons, including Schwann cells and satellite glial cells, and are especially useful to study interactions between neuronal and non-neuronal cells<sup>17</sup>. DRG primary cultures can be easily prepared within 2.5 h. The cell composition and properties are highly reflective of



the source DRG, and as such, specific DRG (lumbar or thoracic DRG) can be collected according to experimental demands. Cultures of embryonic and neonatal DRG neurons require NGF to survive and induce axon outgrowth, but cultures of adult neurons do not require the addition of neurotrophic factors to the media<sup>12,17</sup>. There are also commercially available DRG-hybridoma cell lines such as ND7/23 and F11, which do not require the use of experimental animals. However, the lack of the transient receptor potential cation channel subfamily V member 1 (TRPV1) expression (an important marker for small sensory nociceptive neurons) and incongruent gene expression profiles limit their applications<sup>18</sup>. Recently, immortalized DRG neuronal cell lines have been derived from rat (50B11)<sup>19</sup> and mouse (MED17.11)<sup>20</sup>, which are suitable for use in high-throughput screens for drug targeting studies. However, gene expression profiling for these cell lines has yet to be performed. Thus, the validation experiments comparing these immortalized cells to sensory neurons are still ongoing.

NPFFR2 is synthesized in the DRG and translocated to the sensory nerve terminals in the spinal dorsal horn<sup>21</sup>. In this article, we provide a protocol for culturing lumbar DRG cells and treating them with an agonist of NPFFR2 to induce the release of neurotransmitters, CGRP and SP. The dependence on NPFFR2 is further tested using NPFFR2 small interfering RNA (siRNA), which may be transfected into the cultured DRG cells.

## **PROTOCOL:**

All methods described herein that use experimental animals were approved by the Institutional Animal Care and Use Committee (IACUC) of Chang Gung University (CGU 13-014).

### **1. Collect Lumbar DRG from Experimental Rats**

#### **1.1. Use 2 to 3-week-old Sprague-Dawley (SD) rats for lumbar DRG collection.**

Note: DRG neurons collected from rats over 4 weeks of age do not grow well under the culture conditions described herein.

#### **1.2. Sterilize all surgical instruments in an autoclave.**

**1.3.** Anesthetize the rat with a 1:1 mixture of tiletamine and zolazepam (20 mg/kg; intraperitoneal injection (IP)) and wait until the animal shows no foot-withdrawal response in a toe-pinch test.

Note: Different anesthesia strategies can be used successfully in this protocol.

#### **1.4. Sacrifice the rat by decapitation with a commercial guillotine.**

**1.5.** Use the guillotine to isolate the body trunk of the rat between the forelimb and femur. See **Figure 1A** for a diagram of the region to be collected.

Note: The caudal cut line should be just rostral to the femur. The lumbar L6 DRG will be excised

if the cut site is too high in the spinal column.

1.6. Cut along the sternum and remove all organs/tissues with dissection scissors (**Figure 2A-a**).

1.7. Cut along the side of trunk to collect the dorsal part of the rat and remove the skin. See **Figure 1B** for a photograph of the dissected dorsal trunk.

1.8. Prepare the tissue on ice before collecting DRG. Clean the fur and blood from gloves, and sterilize them with 75% ethanol before proceeding to the next step.

1.9. Remove the muscles covering the lumbar spine. First, make two cuts along the sides of the spinal column (left and right) and one lateral cut to mark the rostral extent of the lumbar spine. Then, remove the dorsal muscles of the spine with bone cutting forceps (**Figure 2A-b**).

1.10. Remove the dorsal portion of the vertebrae with bone cutting forceps and expose the spinal cord.

1.11. Remove the spinal cord with dissection scissors (**Figure 2A-c**) and forceps (**Figure 2A-d**).

1.12. Identify the lumbar DRG by counting vertebrae from the last rib (Thoracic Vertebra 13). See **Figure 1C** for a diagram of the vertebrae positions.

1.13. Collect the bilateral lumbar DRG (L1–L6) with micro-scissors (**Figure 2A-f**) into a 35-mm culture dish with 2 mL ice-cold serum-free medium. Remove the neuronal fibers (as indicated in **Figure 1C**) from connecting DRG, then transfer it into the culture dish to improve the purity of the cultures.

Note: The collected DRG can be kept in medium on ice for about 1 h. Meanwhile, multiple rats can be euthanized to create a larger pool of DRG.

## 2. Primary Culture of Rat Lumbar DRG

Note: The following steps should be performed in a laminar flow hood.

2.1. Prepare culture medium containing 10% fetal bovine serum, 100 mM sodium pyruvate, and 1X penicillin/streptomycin in 1X DMEM-F12.

2.2. Coat the cell-culture treated 24-well plate with 200 µg/mL poly-L-lysine for 2 h then wash with sterilized water.

2.3. Pre-incubate the culture dish with 1 mL culture medium in a 37 °C CO<sub>2</sub> incubator before use for least 30 min.

2.4. Transfer the DRG-containing 35-mm dish into a laminar hood, and wash the DRG with serum-

free medium 3 times by pipette.

Note: The outside of the dish should be cleaned with 75% ethanol before transferring into the hood. The 35-mm dish can contain DRG from a number of rats (this will depend on the demands of the experimental design).

2.5. Move the DRG (from a single rat or combined from multiple rats) to a new 35-mm culture dish, which contains 2 mL of collagenase type IA (1 mg/mL in serum-free medium) with sterile tweezers (**Figure 2A-e**).

Note: The collagenase solution should be sterilized by passing it through a 0.22  $\mu$ m syringe filter.

2.6. Digest the DRG in the collagenase solution in a 37 °C CO<sub>2</sub> incubator for 30 min.

2.7. Remove the collagenase solution and wash the DRG 3 times in 2 mL Hank's balanced salt solution (HBSS).

Note: There may be residual fibers or tissues that come off the DRG into the solution. Remove them by pipette with the washing solution.

2.8. Add 2 mL pre-warmed 0.05% trypsin-EDTA into the DRG-containing 35-mm dish and digest the DRG in a 37 °C CO<sub>2</sub> incubator for 30 min.

2.9. Transfer the 2 mL of DRG-containing solution to a 15 mL centrifuge tube by glass pipette.

Note: The DRG might stick to the glass pipette so this step should be performed with care. DRG loss can be avoided by keeping the DRG-containing solution in the tapered end of a glass pipette (about 0.5 mL) and transferring the solution into the centrifuge tube slowly but without pause.

2.10. Centrifuge the solution at 290 x g for 5 min at 4 °C. Remove the supernatant and add another 2-mL serum-free medium to resuspend the DRG.

2.11. Repeat step 2.10 2 times but change the serum-free medium to pre-warmed culture medium on the last time.

2.12. Manually triturate the DRG approximately 60 times using a flame-polished Pasteur pipette (length 230 mm and tip head inner diameter 1 mm). See **Figure 2B** for a photograph comparing the orifice of a flame-polished Pasteur pipette to a non-polished pipette.

Note: The inside diameter of the flame-polished Pasteur pipette is approximately 10% smaller than the control pipette and the inside of the tapered end should be smoother. Be careful not to create bubbles when triturating the cells.

2.13. Remove the poly-L-lysine-coated dish from the CO<sub>2</sub> incubator. Aspirate the incubated

culture medium from the dish, and seed the dissociated cells onto the coated dish.

2.14. Seed the DRG cells from one rat (bilateral collection from L1–L6, for 12 total DRG) into four wells of a 24-well plate; there are approximately  $5 \times 10^4$  cells in one well of a 24-well plate.

Note: This density is suitable for the detection of the released CGRP or SP and also suitable for immunostaining. For Western blot or RNA extraction, seed the DRG cells from one rat (bilateral L1–L6) into one well of a 6-well plate.

2.15. Replace the culture medium on the following day with the addition of  $10 \mu\text{M}$  cytarabine (Ara-C) and  $100 \text{ ng/mL}$  NGF, and refresh the medium every two days thereafter.

Note: The thoracic DRG also can be cultured by this protocol, if they have been collected from the thoracic spine.

### 3. Transfection of NPFFR2 siRNA in DRG Cells

3.1. Perform the transfection of NPFFR2 siRNA and control siRNA according to the manufacturer's protocol.

Note: The protocol will need to be adapted if the chosen transfection reagent is different from the one we used (see the **Table of Materials**).

3.2. On Day 3 after cell plating, change the medium to  $0.5 \text{ mL}$  pre-warm serum-free medium and incubate the DRG in a  $37^\circ\text{C}$   $\text{CO}_2$  incubator for  $1 \text{ h}$ .

3.3. Add  $50 \text{ nM}$  of siRNA (in  $1 \mu\text{L}$  RNase-free water) into  $12.5 \mu\text{L}$  serum-free medium.

3.4. Add  $2.5 \mu\text{L}$  transfection reagent into  $10 \mu\text{L}$  serum-free medium.

3.5. Mix the solution from steps 3.3 and 3.4 by pipette, and incubate this mixed transfection solution for  $10 \text{ min}$  at room temperature.

3.6. Add the transfection solution into one DRG-containing 24-well plate and mix the solution with medium by gentle shaking.

Note: Multiple transfection solutions should be deployed at the same time if multiple wells need to be transfected.

3.7. Incubate the DRG in a  $37^\circ\text{C}$   $\text{CO}_2$  incubator for  $6 \text{ h}$ .

3.8. Add  $0.5 \text{ mL/well}$  of culture medium containing  $20\%$  fetal bovine serum,  $100 \text{ mM}$  sodium pyruvate, and  $1\text{X}$  penicillin/streptomycin in  $1\text{X}$  DMEM-F12, with the addition of  $10 \mu\text{M}$  Ara-C and  $100 \text{ ng/mL}$  NGF, into the 24-well plate.

3.9. Incubate the DRG in a 37 °C CO<sub>2</sub> incubator for another 66 h (refresh the medium at 48 h).

#### 4. Release of Neurotransmitters from Primary DRG Cells

4.1. On Day 6 after cells were plated (72 h after siRNA transfection), change the culture medium to 200 µL serum-free medium, and incubate the cells in a 37 °C CO<sub>2</sub> incubator for 30 min.

4.2. Add 1 µL stimulation chemical(s) and gently mix the media by pipetting. Incubate the dish in a 37 °C CO<sub>2</sub> incubator for the designated time.

Note: In this article, the cultured cells were stimulated with the NPFFR2 agonist, dNPA (D.Asn-Pro-(N-Me)Ala-Phe-Leu-Phe-Gln-Pro-Gln-Arg- Phe-NH<sub>2</sub>, 5 nmol), for 1 h.

4.3. Collect the culture medium from the culture dish and centrifuge at 5,000 x g for 5 min at 4 °C to remove any suspended impurities.

4.4. Collect the supernatant from the centrifugation and dilute the samples with phosphate-buffered saline (PBS), as needed. Assay the levels of neurotransmitters with enzyme immunoassay (EIA) kits.

Note: Here, the supernatants were diluted 1:100 before analyzing the level of CGRP. The supernatant was not diluted before analyzing the level of SP.

#### 5. CGRP and SP EIA

5.1. Analyze the samples immediately according to the CGRP or SP EIA kit manufacturer's protocol.

Note: The protocol will vary depending on the kit used.

5.2. Rinse the CGRP EIA wells 5 times with wash buffer supplied within the kit.

5.3. Add 100 µL samples with 100 µL anti-CGRP acetylcholinesterase (AChE) tracer into the CGRP EIA wells, and add 50 µL samples, 50 µL anti-SP AChE tracer and 50 µL anti-SP antiserum into the SP EIA wells.

5.4. Seal the CGRP and SP wells with plastic film which is supplied within the kits.

5.5. Incubate the wells overnight at 4 °C.

5.6. Wash the wells 5 times with CGRP or SP wash buffer and remove all the residual solution from the wells.

5.7. Add 200  $\mu$ L Ellman's reagent into the CGRP or SP wells which is supplied within the corresponding EIA kits.

5.8. Incubate the CGRP wells for 30 min at room temperature, and incubate the SP wells for 90 min at room temperature. Protect the wells from light for both assays.

5.9. Read the plates at wavelength 414 nm and calculate the results according to the corresponding EIA instrument.

Note: Avoid touching the bottom of the wells by hand all the time and clean the water stains from the well bottom by lens cleaning wipes before adding the Ellman's reagent.

#### REPRESENTATIVE RESULTS:

Rat lumbar DRG neurons, cultured in a 24-well plate, were grown in culture medium with additional Ara-C to inhibit glial cell proliferation and NGF to support neuronal growth. The morphology of living DRG cells was observed. As shown in **Figure 3**, the cell body of a single neuron was attached on the bottom of a dish at Day 1 and selected for observation. Axon growth was monitored from Day 1–3. The glial cells duplicated and extended processes to surround the cell body of the sensory neuron. In another culture, CGRP protein was stained to reveal the shape of neurons. In **Figure 4**, CGRP protein staining appears in the cytoplasm and axons of sensory neurons. The nuclear morphologies of neurons and glial cells are distinct when stained with DAPI. The neurons have a larger and more rounded nucleus than glial cells. By comparison, the nuclei of glia are more oval in shape (**Figure 4B**).

The selective NPFFR2 agonist, dNPA, was used to stimulate the release of CGRP and SP. Moreover, the dependence of dNPA-stimulated neurotransmitter release on NPFFR2 was tested by transfecting cells with NPFFR2 siRNA. NPFFR2 siRNA or control siRNA were transfected into the primary DRG cells 72 h prior to agonist treatment. DRG cells were treated with dNPA (5 nmol) for 1 h and the release of CGRP and SP was measured by separate EIA kits. The stimulation of DRG with dNPA increased the level of CGRP and SP in the media (**Figure 5A, B**). However, only the dNPA-induced CGRP release was inhibited by expression of NPFFR2 siRNA in cultured DRG cells. The results shown in **Figure 5** were modified from a previous publication and are used here with permission<sup>22</sup>.

#### FIGURE AND TABLE LEGENDS:

**Figure 1: Tissue processing diagrams.** Lumbar DRG are collected from 3-week-old rats. (A) The positions where the guillotine should be used to cut the animal are indicated by dotted lines. (B) The dorsal trunk with skin removed and (C) the locations of lumbar DRG (from L1–L6) are shown. The insert represents the DRG and the connecting fibers (which are indicated by the arrows).

**Figure 2: Special equipment needed for isolating DRG primary cultures.** (A) Surgical instruments used in the collection of DRG. From left to right: (a) dissection scissors (large), (b) bone cutting forceps, (c) dissection scissors (small), (d, e) point tweezers, and (f) micro-scissors. (B) A regular

Pasteur pipette and a flame-polished Pasteur pipette. “a” denotes the inside diameter of regular Pasteur pipette, and “b” denotes the inside diameter of the flame-polished Pasteur pipette.  $b/a \approx 0.9$ .

**Figure 3: The morphology of living DRG cells.** Live DRG cells were monitored by microscopy. Cells are shown (A) one day after seeding, (B) two days after seeding, and (C) three days after seeding. Arrows indicate neuron and arrowheads indicate glia. Scale bar: 20  $\mu$ m.

**Figure 4: Immunostaining of cultured DRG cells.** DRG cells were immunostained with anti-CGRP antibody to show neurons, and 4',6-diamidino-2-phenylindole (DAPI) for the nuclei of neurons and glial cells. (A) CGRP protein was expressed in sensory neuron cell bodies and axon fibers. (B) Nuclei of neurons and glia were stained with DAPI. (C) Merged picture from A and B. Arrow indicates a neuron and arrowhead indicates a glial cell. Scale bar: 30  $\mu$ m.

**Figure 5: The release of neurotransmitters from cultured DRG cells.** The selective NPFFR2 agonist, dNPA, was used to stimulate the release of CGRP and SP from DRG cultures. The dependence of neurotransmitter release on NPFFR2 was verified by transfecting cells with NPFFR2 siRNA. (A and B) After DRG cells were transfected with NPFFR2 siRNA or non-targeting control siRNA (72 h), dNPA (5 nmol) was applied for 1 h to induce the release of CGRP and SP. Data are expressed as mean  $\pm$  standard error of the mean (SEM) and were analyzed by two-way analysis of variance (ANOVA) with Bonferroni *post hoc* tests.  $**p < 0.01$ ,  $***p < 0.001$ ; compared to corresponding vehicle controls (N = 12 per group). Panels A and B have been modified from Lin *et al.*<sup>22</sup>

## DISCUSSION:

In the present article, we demonstrate the collection, enzyme-dissociation, and culture of rat lumbar DRG. With the neurotrophic support from NGF, the axons of DRG neurons extended within 3 days after cell seeding. The extended axons were clearly observable after cells were stained for CGRP protein, which is synthesized in the cell soma and transported along the axon fibers. The processes of satellite cells also extended, allowing these dividing glial cells to surround the neurons within days. The primary DRG cells grown by this protocol are suitable for investigations into the cellular mechanisms that regulate sensory neurons. Here, we stimulate the release of neuropeptides, CGRP and SP, from cultured DRG neurons by a selective NPFFR2 agonist, dNPA. NPFFR2 is the cognate receptor for NPFF and has been reported to participate in pain sensation and regulation pathways<sup>22,23</sup>. The NPFFR2-dependence of CGRP and SP release was further verified by the use of NPFFR2 siRNA.

DRG cultures contain both sensory neurons and satellite glial cells. The satellite glial cells provide metabolic support to neurons and maintain neuronal functions<sup>9,10</sup>. In the immunostaining pictures, it is easy to identify the neurons and glial cells, since their nuclei are shaped differently (show in **Figure 4B**). The existence of satellite cells in the culture dish might become problematic if there is an experimental demand to distinguish between the specific function of neurons and glia. For example, it is undeniable that satellite cells are involved in the development and maintenance of pain<sup>11,24</sup>, and in some studies, the actions of neurons and glial cells would be

difficult to distinguish using DRG cultures.

In this protocol, there are a few critical steps that require extra caution. First, since the DRG are collected outside of the laminar hood, extra care should be taken during the tissue collection process to avoid cell contamination. There should be no need to create a sterile space, like in a human surgical room, but instrument sterilization and a clean operating space are essential. Tips to avoid contamination include keeping the sterilized instruments on the sterilization pouch when not in use and avoiding the touching of any unnecessary items. Also, contaminating organisms may be carried on fur that may stick to the rat body trunk or gloves. As such, fur and bloodstains on gloves should be removed by cleaning with 75% ethanol. It is also helpful for the operator to wear a surgical mask to prevent transfer of organisms from the breath or saliva. Furthermore, the 35-mm dish should be kept closed at all the times and only opened when placing dissected DRG inside. It is important to replace the 35-mm dish with a new dish before enzyme digestion. During enzyme digestion, do not extend the incubation time, since over-digestion may damage the neurons. Make sure to pre-warm the trypsin-EDTA to 37 °C in order to achieve appropriate digestion efficiency. The efficiency will be dramatically reduced in lower temperatures, and it will be difficult to achieve a single cell suspension when triturating the DRG by flame-polished Pasteur pipette. Flame polishing the pipette will smooth the orifice and prevent the sharp glass edge from injuring the neurons. However, overheating the pipette with a flame will make the inside diameter too small, and tissue- or cell-containing solution will become difficult to pass through. This reduced diameter may also cause many bubbles to form during the trituration stage, greatly reducing the collectable number of DRG neurons. Finally, DRG cultures should be handled gently at all times, especially when changing medium or performing drug treatment.

The DRG neurons are reported to be the most frequently used primary cultured neuronal cells<sup>12</sup>. They can be utilized for a variety of different studies, ranging from electrophysiology or cell biology to exploring the physiological or pathological functions of sensory neurons. The major limitation of DRG primary cultures is that they are not well-suited for high-throughput screening. The number of cells that may be collected from the DRG of a single rat are limited, and the neurons are unable to duplicate in culture. Because of the limited cell number, several DRG-hybridoma cell lines or immortalized DRG neuronal cell lines have been developed to replace the primary cultures<sup>18-20</sup>. However, the protein expression profiles of DRG cell lines might not be the same as the original DRG and, thus, each model system needs to be carefully verified. Aside from isolating the cells in the lab, rat embryonic or neonatal DRG neurons have been made commercially available. Therefore, purchase from commercial sources may be a viable alternative to freshly prepared DRG cultures.

DRG primary cultures have been used for many years as a valuable experimental tool that is mostly adopted in pain-related studies. This model system is unlikely to be replaced in the near future. With good quality DRG neurons, scientists can obtain stable and reproducible results that benefit many areas of neuroscience study.

#### **ACKNOWLEDGMENTS:**



We thank Dr. M. Calkins for English editing. This work was supported by the Chang Gung Memorial Hospital (CMRPD1F0482), Chang Gung University, Healthy Aging Research Center (EMRPD1G0171) and Ministry of Science and Technology (105-2320-B-182-012-MY2).

#### DISCLOSURES:

The authors have nothing to disclose.

#### REFERENCES:

- 1 Bear, M. F., Connors, B. W. & Paradiso, M. A. *Neuroscience : exploring the brain*. 3 edn, (Lippincott Williams & Wilkins, 2007).
- 2 Hunt, S. P. & Mantyh, P. W. The molecular dynamics of pain control. *Nat Rev Neurosci.* **2** (2), 83-91, doi:10.1038/35053509, (2001).
- 3 Kandel, E. R., Schwartz, J. H. & Jessell, T. M. *Principles of neural science*. 3 edn, (McGraw-Hill, Health Professions Division, 2000).
- 4 Julius, D. & Basbaum, A. I. Molecular mechanisms of nociception. *Nature.* **413** (6852), 203-210, doi:10.1038/35093019, (2001).
- 5 Sah, D. W., Ossipo, M. H. & Porreca, F. Neurotrophic factors as novel therapeutics for neuropathic pain. *Nat Rev Drug Discov.* **2** (6), 460-472, doi:10.1038/nrd1107, (2003).
- 6 Coutaux, A., Adam, F., Willer, J. C. & Le Bars, D. Hyperalgesia and allodynia: peripheral mechanisms. *Joint Bone Spine.* **72** (5), 359-371, doi:10.1016/j.jbspin.2004.01.010, (2005).
- 7 Basbaum, A. I., Bautista, D. M., Scherrer, G. & Julius, D. Cellular and molecular mechanisms of pain. *Cell.* **139** (2), 267-284, doi:10.1016/j.cell.2009.09.028, (2009).
- 8 Marchand, F., Perretti, M. & McMahon, S. B. Role of the immune system in chronic pain. *Nat Rev Neurosci.* **6** (7), 521-532, doi:10.1038/nrn1700, (2005).
- 9 Hanani, M. Satellite glial cells in sensory ganglia: from form to function. *Brain Res Brain Res Rev.* **48** (3), 457-476, doi:10.1016/j.brainresrev.2004.09.001, (2005).
- 10 Nascimento, R. S., Santiago, M. F., Marques, S. A., Allodi, S. & Martinez, A. M. Diversity among satellite glial cells in dorsal root ganglia of the rat. *Braz J Med Biol Res.* **41** (11), 1011-1017 (2008).
- 11 Costa, F. A. & Moreira Neto, F. L. [Satellite glial cells in sensory ganglia: its role in pain]. *Rev Bras Anesthesiol.* **65** (1), 73-81, doi:10.1016/j.bjan.2013.07.013, (2015).
- 12 Malin, S. A., Davis, B. M. & Molliver, D. C. Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. *Nat Protoc.* **2** (1), 152-160, doi:10.1038/nprot.2006.461, (2007).
- 13 Lin, Y. T., Ro, L. S., Wang, H. L. & Chen, J. C. Up-regulation of dorsal root ganglia BDNF and trkB receptor in inflammatory pain: an in vivo and in vitro study. *J Neuroinflammation.* **8** 126, doi:10.1186/1742-2094-8-126, (2011).
- 14 Liem, L., van Dongen, E., Huygen, F. J., Staats, P. & Kramer, J. The Dorsal Root Ganglion as a Therapeutic Target for Chronic Pain. *Reg Anesth Pain Med.* **41** (4), 511-519, doi:10.1097/AAP.0000000000000408, (2016).
- 15 Lee, J. S., Han, J. S., Lee, K., Bang, J. & Lee, H. The peripheral and central mechanisms underlying itch. *BMB Rep.* **49** (9), 474-487 (2016).
- 16 Valtcheva, M. V. *et al.* Surgical extraction of human dorsal root ganglia from organ donors and preparation of primary sensory neuron cultures. *Nat Protoc.* **11** (10), 1877-1888,

doi:10.1038/nprot.2016.111, (2016).

17 Melli, G. & Hoke, A. Dorsal Root Ganglia Sensory Neuronal Cultures: a tool for drug  
discovery for peripheral neuropathies. *Expert Opin Drug Discov.* **4** (10), 1035-1045,  
doi:10.1517/17460440903266829, (2009).

18 Yin, K., Baillie, G. J. & Vetter, I. Neuronal cell lines as model dorsal root ganglion neurons:  
A transcriptomic comparison. *Mol Pain.* **12**, doi:10.1177/1744806916646111, (2016).

19 Chen, W., Mi, R., Haughey, N., Oz, M. & Hoke, A. Immortalization and characterization of  
a nociceptive dorsal root ganglion sensory neuronal line. *J Peripher Nerv Syst.* **12** (2), 121-130,  
doi:10.1111/j.1529-8027.2007.00131.x, (2007).

20 Doran, C., Chetrit, J., Holley, M. C., Grundy, D. & Nassar, M. A. Mouse DRG Cell Line with  
Properties of Nociceptors. *PLoS One.* **10** (6), e0128670, doi:10.1371/journal.pone.0128670,  
(2015).


21 Gouarderes, C., Roumy, M., Advokat, C., Jhamandas, K. & Zajac, J. M. Dual localization of  
neuropeptide FF receptors in the rat dorsal horn. *Synapse.* **35** (1), 45-52, doi:10.1002/(SICI)1098-  
2396(200001)35:1<45::AID-SYN6>3.0.CO;2-0, (2000).



22 Lin, Y. T. *et al.* Activation of NPFFR2 leads to hyperalgesia through the spinal inflammatory  
mediator CGRP in mice. *Exp Neurol.* **291** 62-73, doi:10.1016/j.expneurol.2017.02.003, (2017).

23 Yang, H. Y., Tao, T. & Iadarola, M. J. Modulatory role of neuropeptide FF system in  
nociception and opiate analgesia. *Neuropeptides.* **42** (1), 1-18, doi:10.1016/j.npep.2007.06.004,  
(2008).



24 Takeda, M., Takahashi, M. & Matsumoto, S. Contribution of the activation of satellite glia  
in sensory ganglia to pathological pain. *Neurosci Biobehav Rev.* **33** (6), 784-792,  
doi:10.1016/j.neubiorev.2008.12.005, (2009).

Figure 1


















Figure 5



Name of Material/ Equipment	Company	Catalog Number	Comments/Description
Mixture of tiletamine and zolazepam (Zoletil)	Virbac Biological	Zoletil 50	anaesthetic
Fetal bovine serum	Industries	04-001-1	Culture Medium
sodium pyruvate	Sigma Biological	S8636	Culture Medium
penicillin/streptomycin	Industries	03-033-1	Culture Medium
DMEM-F12	Invitrogen	12400024	Culture Medium
Poly-l-lysine	Sigma	P9011	Coating dish
Collagenase IA	Sigma	9001-12-1	Enzyme digestion
Hank's balanced salt solution	Invitrogen Biological	14170-112	Culture Medium
Trypsin EDTA	Industries	03-051-5	Enzyme digestion
Pasteur pipette	Hilgenberg	3150102	Cell trituration
Cytarabine (Ara-C)	Sigma	C6645	Culture Medium
NGF	Millipore	NC011	Culture Medium
NPFFR2 siRNA	Dharmacon	L-099691-02-0005	Transfection
Non-targeting siRNA	Dharmacon	L-001810-10-05	Transfection
NeuroPORTER Reagent	Genlantis Genemed	T400150	Transfection reagent
dNPA	Synthesis	N/A	NPFFR2 agonist
CGRP ELISA	Cayman	589001	EIA
SP ELISA	Cayman	583751	EIA
CGRP antibody	Calbiochem	PC205L	IHC
DAPI	Roche	10236276001	IHC





1 Alewife Center #200  
 Cambridge, MA 02140  
 tel. 617.945.9051  
 www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article: Application of dorsal root ganglia primary cultures to studies of neurotransmitter release  
 Author(s): Ya-Tin Lin, Jin-Chung Chen

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.  
☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.  
☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

## ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have



## ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assigns. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

### CORRESPONDING AUTHOR:

Name:

Jin-Chung Chen

Department:

Physiology and Pharmacology


Institution:

Chang-Gung University

Article Title:

Application of dorsal root ganglia primary cultures to studies of neurotransmitter release

Signature:



Date:

Nov. 9, 2017

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email [submissions@jove.com](mailto:submissions@jove.com) or call +1.617.945.9051

## Changes recommended by the JoVE Scientific Review Editor:

Protocol:

**1) 2.2:** Mention dish type and size.

**Ans:** The cell-culture treated 24-well plate was used and we have mentioned it in Protocol 2.2.

**2) 2.4:** Does one 35-mm contain DRG from 1 rat?

**Ans:** It depends on how many wells the operator wants to use at the experimental days. In Protocol 2.14, we mentioned that DRG cells from one rat (bilateral collection from L1-L6, equals 12 total DRGs) can be seeded into four wells of a 24-well plate. To clarify the issue, we have added a sentence in the Note of Protocol 2.4.

**3) 2.5:** Again, DRG from 1 rat in one 35-mm dish? How much Medium?

**Ans:** As answered in above question, it depends on the demands of experimental design. The 35-mm dish contains 2 mL of collagenase type IA (1 mg/mL in serum-free medium). To clarify the issue, We have added a sentence in the Note of Protocol 2.5.

**4) DRG and DRGs** are used interchangeably, please be consistent and try to stick with 1.

**Ans:** We have replaced all the DRGs in the manuscript with DRG.

**5) 2.12:** Mention pipette tip diameter/size. What is the control pipette tip size?

**Ans:** The length of the Pasteur pipette is 230 mm and the tip head inner diameter is 1 mm. The control pipette is exactly the same but has not been polished by flame. We have added a sentence in Protocol 2.12.

**6) In 2.13:** mention incubation temperature and duration. How much culture medium? Are the cells counted? If so, how?

**Ans:** The incubation temperature, duration and the volume of culture medium have been mentioned at Protocol 2.3. The cells were not counted for each experiment. The 12 DRG (bilateral L1~L6) from a single rat were seeded into four wells of a 24-well plate and we always have control group when treated the cells with drugs. However, there are approximately  $5 \times 10^4$  cells in one well of a 24-well plate. We have added this information in Protocol 2.14.

**7) 2.15:** By 'change medium', do you mean 'refresh medium'?

**Ans:** Yes, we have replaced the word form "change" to "refresh" in Protocol 2.15.

**8) 3.3:** Collect the supernatant from the culture dish?

**Ans:** Yes, we have modified the sentence to make it more clear in Protocol 4.3 (the original 3.3).

**9) 3.4: Supernatant from the centrifugation in 3.3?**

**Ans:** Yes, we have modified the sentence to make it more clear in Protocol 4.4 (the original 3.4).

- Protocol Numbering: There must be a one-line space between each protocol step.
- Protocol Highlight: After you have made all of the recommended changes to your protocol (listed above), please reevaluate the length of your protocol section. There is a 10-page limit for the protocol text, and a 3- page limit for filmable content. If your protocol is longer than 3 pages, please highlight ~2.5 pages or less of text (which includes headings and spaces) in yellow, to identify which steps should be visualized to tell the most cohesive story of your protocol steps. Please see JoVE's instructions for authors for more clarification. Remember that the non-highlighted protocol steps will remain in the manuscript and therefore will still be available to the reader.

**Ans:** We have added one-line space between each protocol step and highlighted the steps for video filming in gray (from Protocol 1 to 2.14).

- Discussion:

JoVE articles are focused on the methods and the protocol, thus the discussion should be similarly focused. Please ensure that the discussion covers the following in detail and in paragraph form: 1) modifications and troubleshooting, 2) limitations of the technique, 3) significance with respect to existing methods, 4) future applications and 5) critical steps within the protocol.

**Ans:** All the above information has been included in the Discussion section.

- Figures:

**1) Fig 5A:** mention units for the molecular weights.

**Ans:** The unit of molecular weights is kDa. However, we remove the figure 5A from the revised text since it did not carry extra information and rather might mislead the readers.

- Commercial Language:

JoVE is unable to publish manuscripts containing commercial sounding language, including trademark or registered trademark symbols (TM/R) and the mention of company brand names before an instrument or reagent. Examples of commercial sounding language in your manuscript are Zoletil, 1) Please use MS Word's find function (Ctrl+F), to locate and replace all commercial sounding language in your manuscript with generic names that are not company-specific.

**Ans:** The name of commercial anesthetics Zoletil has been replaced by its composition in Protocol 1.3.

All commercial products should be sufficiently referenced in the table of materials/reagents. You may use the generic term followed by "(see table of materials)" to draw the readers' attention to

specific commercial names.

**Ans:** We have uploaded a table of materials which includes all the commercial products used in this article.

- Please define all abbreviations at first use.

**Ans:** All the abbreviations have been defined at first use.

- Please use standard abbreviations and symbols for SI Units such as  $\mu\text{L}$ , mL, L, etc., and abbreviations for non-SI units such as h, min, s for time units. Please use a single space between the numerical value and unit.

**Ans:** We have used standard abbreviations and symbols for SI and non-SI Units.

- If your figures and tables are original and not published previously or you have already obtained figure permissions, please ignore this comment. If you are re-using figures from a previous publication, you must obtain explicit permission to re-use the figure from the previous publisher (this can be in the form of a letter from an editor or a link to the editorial policies that allows you to re-publish the figure). Please upload the text of the re-print permission (may be copied and pasted from an email/website) as a Word document to the Editorial Manager site in the "Supplemental files (as requested by JoVE)" section. Please also cite the figure appropriately in the figure legend, i.e. "This figure has been modified from [citation]."

**Ans:** The figures 5A and 5B were modified from our previous publication and we have cited it in the figure legend 5. We also have uploaded the figure permission document with this submission.

## Comments of Reviewer #1:

**1)** The authors only said "On the experimental day" in the "Release of neurotransmitters from primary DRG cells." Which day? Because we still could find many glial cells on three days after seeding.

**Ans:** We measured the release of neurotransmitters on the sixth day after the cells were planted (72 h after siRNA transfection). The proliferation of glial cells was significantly inhibited by the addition of AraC, but glia cells remain existed. Since CGRP and SP do not express in the glial cells, the analyses would not affect the results. However, we still view this as a limitation of the DRG primary culture and discussed it in the second paragraph of Discussion.

**2)** The methods for ELISA were missing.

**Ans:** The samples were analyzed according to the manufacturer's protocols of CGRP and SP EIA. We have added a brief description in Protocol 5.

**3)** Why did authors dilute the supernatants for analyzing the level of CGRP and did not dilute the supernatants for analyzing the level of SP?

**Ans:** This is based on the levels difference of CGRP and SP in the culture medium as well as the detection sensitivity of individual ELISA kits. Thus, different dilution should be adjusted if different brand of ELISA kit is used.

**4)** Why did authors apply 5 nmol dNPA and culture for 1 hr, respectively.

**Ans:** The dose-dependent effects of dNPA were tested and published previously (see following reference). Base on those results, the 5 nmol is the best choice. We also tested the duration of the drug treatment in a pioneer study. The duration of 1 hr incubation accumulates enough detectable neurotransmitters that can reflect the response to drugs.

#### **Reference**

Lin, Y. T. *et al.* Activation of NPFFR2 leads to hyperalgesia through the spinal inflammatory mediator CGRP in mice. *Exp Neurol.* **291** 62-73, doi:10.1016/j.expneurol.2017.02.003, (2017).

**5)** In the discussion, the authors did not explain why the neurons could release CGRP and SP under the stimulation of dNPA.

**Ans:** In our previous publication, we have demonstrated that the stimulation of NPFFR2 increases the release of CGRP and SP from the DRG cultures and further reduces the pain threshold on testing mice (see following reference). The figure 5A and 5B were modified from this cited article. Since JOVE is a video article for experimental methods, we follow the author's guideline and the discussion was focused on the methods but not the results.

#### **Reference**

Lin, Y. T. *et al.* Activation of NPFFR2 leads to hyperalgesia through the spinal inflammatory mediator CGRP in mice. *Exp Neurol.* **291** 62-73, doi:10.1016/j.expneurol.2017.02.003, (2017).

**6)** The authors should prove that neurons express NPFFR2.

**Ans:** The NPFFR2 was demonstrated to be synthesized in the DRG and trans-located to the sensory nerve terminals in the spinal dorsal horn (see following reference). We have added one sentence and cited this article in the last paragraph of the Introduction section.

#### **Reference**

Gouarderes, C., Roumy, M., Advokat, C., Jhamandas, K. & Zajac, J. M. Dual localization of neuropeptide FF receptors in the rat dorsal horn. *Synapse.* **35** (1), 45-52, doi:10.1002/(SICI)1098-2396(200001)35:1<45::AID-SYN6>3.0.CO;2-0, (2000).

**7)** The details for NPFFR2 siRNA transfection and western blot were missing.

**Ans:** The details of NPFFR2 siRNA transfection have been added in the Protocol 3. The western blot result from Figure 5 has been removed since it did not explore more information.

## Comments of Reviewer #2:

**1)** The description about the various types of sensory neurons is too long and rather irrelevant. The authors should focus on the quality, limitation and application of cultured sensory neurons.

**Ans:** We have reasonably reduced the description of sensory neurons in the Introduction section. The quality, limitation and application of the sensory neuron are mentioned in the third paragraph of the Introduction, and the first, second and fourth paragraph of the Discussion.

**2)** The authors should also mention that cultured DRG sensory neurons can also be obtained from human (Valtcheva et al., Nature Protocols, 2016).

**Ans:** Authors appreciate reviewer provided us this valuable reference and we have added it into the Introduction (Line 79-80).

**3)** The physical removal of DRG from the foramen is quickly described. Which tweezers are used? Which fibers are removed? Are they removed at the collection or after in the dish?

**Ans:** We identified the surgery equipments by English letters on the Figure 2A and Protocol section to help readers understand which equipments should be used. The fibers of targeted DRG should be removed before transferring the DRG into the culture dishes. We have rephrased the sentence to clarify it (Protocol 1.13) and added a inserted picture in Figure 1C to indicate the location of DRG and its connecting fibers.

**4)** Cells from twelve DRGs are cultured in 4 wells of a 24-well plate. The authors should provide an approximate number of cell per ml. How long the sensory neurons are incubated before use?

**Ans:** There are approximately  $5 \times 10^4$  cells in a single well of a 24-well plate and the experiment of neurotransmitter release was performed at the sixth day after cells were plated (72 h after siRNA transfection). These information has been added in the Protocol 2.14 and 4.1.

**5)** There is no reference for the amount of siRNA used, as well as no details on the transfection method!

**Ans:** 50 nM of siRNA was used in the current study. The details of NPFFR2 siRNA transfection have been added in Protocol 3.



ELSEVIER LICENSE  
TERMS AND CONDITIONS

Oct 31, 2017

This Agreement between Chang Gung University -- Ya-Tin Lin ("You") and Elsevier ("Elsevier") consists of your license details and the terms and conditions provided by Elsevier and Copyright Clearance Center.

License Number	4219191053868
License date	Oct 31, 2017
Licensed Content Publisher	Elsevier
Licensed Content Publication	Experimental Neurology
Licensed Content Title	Activation of NPFFR2 leads to hyperalgesia through the spinal inflammatory mediator CGRP in mice
Licensed Content Author	Ya-Tin Lin, Ho-Ling Liu, Yuan-Ji Day, Che-Chien Chang, Po-Hung Hsu, Jin-Chung Chen
Licensed Content Date	May 1, 2017
Licensed Content Volume	291
Licensed Content Issue	n/a
Licensed Content Pages	12
Start Page	62
End Page	73
Type of Use	reuse in a journal/magazine
Requestor type	author of new work
Intended publisher of new work	Other
Portion	figures/tables/illustrations
Number of figures/tables/illustrations	2
Format	electronic
Are you the author of this Elsevier article?	Yes
Will you be translating?	No
Original figure numbers	Figure 8c, 8d
Title of the article	Application of dorsal root ganglia primary cultures to study the release of neurotransmitter
Publication new article is in	JOVE
Publisher of the new article	JOVE
Author of new article	Ya-Tin Lin, Jin-Chung Chen
Expected publication date	Jan 2018
Estimated size of new article (number of pages)	8
Requestor Location	Chang Gung University 259 Wenhua 1st road Dept. Pharm.  Taoyuan, 333 Taiwan Attn: Chang Gung University
Total	0.00 USD
Terms and Conditions	

## INTRODUCTION

1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at <http://myaccount.copyright.com>).

## GENERAL TERMS

2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated.

3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows:

"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier."

4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given.

5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at [permissions@elsevier.com](mailto:permissions@elsevier.com)). No modifications can be made to any Lancet figures/tables and they must be reproduced in full.

6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee.

7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials.

9. Warranties: Publisher makes no representations or warranties with respect to the licensed material.

10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license.

11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission.

12. No Amendment Except in Writing: This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).

13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement

between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control.

14. **Revocation:** Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.

### LIMITED LICENSE

The following terms and conditions apply only to specific license types:

15. **Translation:** This permission is granted for non-exclusive world **English** rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article.

16. **Posting licensed content on any Website:** The following terms and conditions apply as follows: Licensing material from an Elsevier journal: All content posted to the web site must maintain the copyright information line on the bottom of each image; A hyper-text must be included to the Homepage of the journal from which you are licensing at <http://www.sciencedirect.com/science/journal/xxxxx> or the Elsevier homepage for books at <http://www.elsevier.com>; Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.

Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier homepage at <http://www.elsevier.com>. All content posted to the web site must maintain the copyright information line on the bottom of each image.

**Posting licensed content on Electronic reserve:** In addition to the above the following clauses are applicable: The web site must be password-protected and made available only to bona fide students registered on a relevant course. This permission is granted for 1 year only. You may obtain a new license for future website posting.

17. **For journal authors:** the following clauses are applicable in addition to the above:

#### Preprints:

A preprint is an author's own write-up of research results and analysis, it has not been peer-reviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright, technical enhancement etc.).

Authors can share their preprints anywhere at any time. Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the final versions of articles however authors can update their preprints on arXiv or RePEc with their Accepted Author Manuscript (see below).

If accepted for publication, we encourage authors to link from the preprint to their formal publication via its DOI. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help users to find, access, cite and use the best available version. Please note that Cell Press, The Lancet and some society-owned have different preprint policies. Information on these policies is available on the journal homepage.

**Accepted Author Manuscripts:** An accepted author manuscript is the manuscript of an article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and editor-author communications.

Authors can share their accepted author manuscript:

- immediately
  - via their non-commercial person homepage or blog
  - by updating a preprint in arXiv or RePEc with the accepted manuscript
  - via their research institute or institutional repository for internal institutional uses or as part of an invitation-only research collaboration work-group

- directly by providing copies to their students or to research collaborators for their personal use
- for private scholarly sharing as part of an invitation-only work group on commercial sites with which Elsevier has an agreement
- After the embargo period
  - via non-commercial hosting platforms such as their institutional repository
  - via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:

- link to the formal publication via its DOI
- bear a CC-BY-NC-ND license - this is easy to do
- if aggregated with other manuscripts, for example in a repository or other site, be shared in alignment with our hosting policy not be added to or enhanced in any way to appear more like, or to substitute for, the published journal article.

**Published journal article (JPA):** A published journal article (PJA) is the definitive final record of published research that appears or will appear in the journal and embodies all value-adding publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination and online enrichment.

Policies for sharing publishing journal articles differ for subscription and gold open access articles:

**Subscription Articles:** If you are an author, please share a link to your article rather than the full-text. Millions of researchers have access to the formal publications on ScienceDirect, and so links will help your users to find, access, cite, and use the best available version. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

If you are affiliated with a library that subscribes to ScienceDirect you have additional private sharing rights for others' research accessed under that agreement. This includes use for classroom teaching and internal training at the institution (including use in course packs and courseware programs), and inclusion of the article for grant funding purposes.

**Gold Open Access Articles:** May be shared according to the author-selected end-user license and should contain a [CrossMark logo](#), the end user license, and a DOI link to the formal publication on ScienceDirect.

Please refer to Elsevier's [posting policy](#) for further information.

18. **For book authors** the following clauses are applicable in addition to the above:

Authors are permitted to place a brief summary of their work online only. You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. **Posting to a repository:** Authors are permitted to post a summary of their chapter only in their institution's repository.

19. **Thesis/Dissertation:** If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. Theses and dissertations which contain embedded PJAs as part of the formal submission can be posted publicly by the awarding institution with DOI links back to the formal publications on ScienceDirect.

### **Elsevier Open Access Terms and Conditions**

You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000 established subscription journals that support open access publishing. Permitted third party re-use of these open access articles is defined by the author's choice of Creative Commons user license. See our [open access license policy](#) for more information.

### **Terms & Conditions applicable to all Open Access articles published with Elsevier:**

Any reuse of the article must not represent the author as endorsing the adaptation of the article nor should the article be modified in such a way as to damage the author's honour or reputation. If any changes have been made, such changes must be clearly indicated.

The author(s) must be appropriately credited and we ask that you include the end user license and a DOI link to the formal publication on ScienceDirect.

If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source it is the responsibility of the user to ensure their reuse complies with the terms and conditions determined by the rights holder.

**Additional Terms & Conditions applicable to each Creative Commons user license:**

**CC BY:** The CC-BY license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article and to make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by/4.0>.

**CC BY NC SA:** The CC BY-NC-SA license allows users to copy, to create extracts, abstracts and new works from the Article, to alter and revise the Article, provided this is not done for commercial purposes, and that the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work. Further, any new works must be made available on the same conditions. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-sa/4.0>.

**CC BY NC ND:** The CC BY-NC-ND license allows users to copy and distribute the Article, provided this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <http://creativecommons.org/licenses/by-nc-nd/4.0>. Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires permission from Elsevier and will be subject to a fee.

Commercial reuse includes:

- Associating advertising with the full text of the Article
- Charging fees for document delivery or access
- Article aggregation
- Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.

**20. Other Conditions:**

v1.9

**Questions? [customercare@copyright.com](mailto:customercare@copyright.com) or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.**